Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), designed to stimulate the pituitary gland to release endogenous growth hormone (GH).
- Structure: 44-amino-acid peptide analog of human GHRH.
- Purpose: Enhances natural GH secretion, primarily to reduce visceral fat and improve metabolic parameters.
- Regulatory status: FDA-approved for reducing excess abdominal fat in HIV-associated lipodystrophy.
🧪 Clinical Evidence
Primary Use: Tesamorelin is FDA-approved for HIV-associated lipodystrophy, which causes redistribution of fat (especially in the abdomen).
Efficacy: Clinical trials show:
•Significant reduction of visceral adipose tissue (VAT) after 26–52 weeks of treatment.
•Some improvement in waist circumference and metabolic markers.
•GH-dependent side effects are generally mild and manageable.
Safety Profile:
•Most common side effects: joint pain, swelling, injection site reactions.
•Rare: increased glucose levels, potentially mild insulin resistance.
•Contraindicated in patients with active malignancy or pituitary tumors.
Reviews
There are no reviews yet.